Reporting drugs and treatments Thomas Abraham JMSC 6090.

Slides:



Advertisements
Similar presentations
Basic statistics.
Advertisements

How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
FAST STATS A 5-minute Review for the Evidence-Based Practitioner.
Objective: To test claims about inferences for two proportions, under specific conditions Chapter 22.
Reporting drugs and treatments Thomas Abraham. What we will learn today The difference between absolute and relative risk reduction A basic way to interpret.
Extension Article by Dr Tim Kenny
Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Inference for proportions - Comparing 2 proportions IPS chapter 8.2 © 2006 W.H. Freeman and Company.
Ch 10 Comparing Two Proportions Target Goal: I can determine the significance of a two sample proportion. 10.1b h.w: pg 623: 15, 17, 21, 23.
Inference for proportions - Comparing 2 proportions IPS chapter 8.2 © 2006 W.H. Freeman and Company.
Comparing 2 proportions BPS chapter 21 © 2006 W. H. Freeman and Company These PowerPoint files were developed by Brigitte Baldi at the University of California,
+ Section 10.1 Comparing Two Proportions After this section, you should be able to… DETERMINE whether the conditions for performing inference are met.
8.1 Inference for a Single Proportion
Number Needed to Treat. End Points Baseline Risk is the risk associated with a particular condition Baseline Risk is the risk associated with a particular.
Analyses of Covariance Comparing k means adjusting for 1 or more other variables (covariates) Ho: u 1 = u 2 = u 3 (Adjusting for X) Combines ANOVA and.
How to Analyze Therapy in the Medical Literature (part 2)
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Two-sample Proportions Section Starter One-sample procedures for proportions can also be used in matched pairs experiments. Here is an.
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 10 Comparing Two Groups Section 10.1 Categorical Response: Comparing Two Proportions.
* Chapter 8 – we were estimating with confidence about a population * Chapter 9 – we were testing a claim about a population * Chapter 10 – we are comparing.
Compliance Original Study Design Randomised Surgical care Medical care.
4S: Scandinavian Simvastatin Survival Study
HS 1679B: Comparing Proportions1 9B: Comparing two proportions.
Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
2 3 انواع مطالعات توصيفي (Descriptive) تحليلي (Analytic) مداخله اي (Interventional) مشاهده اي ( Observational ) كارآزمايي باليني كارآزمايي اجتماعي كارآزمايي.
Objectives (Chapter 20) Comparing two proportions  Comparing 2 independent samples  Confidence interval for 2 proportion  Large sample method  Plus.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Proposal to Incorporate Trial Data Into a Hybrid.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
GP ST2 Group, 28/9/11 Tom Gamble
20. Comparing two proportions
HelpDesk Answers Synthesizing the Evidence
Copyright © 2006 American Medical Association. All rights reserved.
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:
CRITICAL NUMBERS LIVING WITH RISK
Confidence Intervals and p-values
Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Copyright © 2002 American Medical Association. All rights reserved.
AIM HIGH Niacin plus Statin to prevent vascular events
Chapter 10: Comparing Two Populations or Groups
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
NAPLEX preparation: Biostatistics
Baseline characteristics of HPS participants by prior diabetes
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Interpreting Basic Statistics
Chapter 10: Comparing Two Populations or Groups
Chapter 10: Comparing Two Populations or Groups
Potential mechanisms whereby statins may reduce the risk of stroke
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
In a simple random sample of 300 elderly men, 65% were married while in an independent simple random sample of 400 elderly women, 48% were married. Determine.
Chapter 10: Comparing Two Populations or Groups
Chapter 10: Comparing Two Populations or Groups
Chapter 10: Comparing Two Populations or Groups
Chapter 10: Comparing Two Populations or Groups
Chapter 10: Comparing Two Populations or Groups
Chapter 10: Comparing Two Populations or Groups
Delahoy PJ, et al. Clin Ther 2009;31:236-44
Characteristics of included studies
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Chapter 10: Comparing Two Populations or Groups
The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%
Basic statistics.
Medical Statistics Exam Technique and Coaching, Part 2 Richard Kay Statistical Consultant RK Statistics Ltd 22/09/2019.
Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.
Presentation transcript:

Reporting drugs and treatments Thomas Abraham JMSC 6090

What we will learn today How to evaluate and report on studies The difference between absolute and relative risk reduction Number needed to treat (NNT) A basic way to interpret P values and CI (confidence intervals)

Nov 1995, results of a new drug trial 6,595 men in the west of Scotland with elevated cholesterol levels participated in trial that lasted 5 years One group (treatment group) was given a cholesterol lowering drug, pravastatin Another group (control group) was given a placebo

The results were impressive For those who took the drug: 31 % reduction of risk from heart attacks 28 % reduction of risk of death from coronary heart disease 31 % reduction of risk from heart attack, or death from heart disease

7.9% 5.5% Combined risk from heart attacks and death from heart disease

A 7.9% B 5.5% Control groupTreatment group How do you measure the difference between these two groups? Risk from heart attack and death from heart disease

Absolute and relative risk reduction Absolute risk reduction looks at the difference between the treatments: A-B =2.4% Relative risk reduction looks at how much better one treatment is than the other (A-B/ A) x 100=30.37% A Control group B Treatment Group 7.9% 5.5%

Absolute and relative risk Absolute risk is your risk of getting a particular disease, or condition Relative risk measures how much your risk is reduced with the new treatment, or procedure, compared with the old. Relative risk figures tend to look dramatic

Control: 1.7%; treatment 1.2% Absolute risk reduction= Relative risk reduction=

A Control 6.5% B Treatm ent 4.6% Non fatal Myocardial Infarction Absolute Risk Reduction = ? Relative risk Reduction= ?

What were the different outcomes the study measured? Which outcome was the treatment the most effective in?

Number needed to Treat (NNT) The number of persons who needed to be treated with a drug, to prevent one person from getting the disease. Calculated as the inverse of the absolute risk reduction percentage

Absolute Risk Reduction = A-B=.5%. 5% means out of 100 people,.5 death was prevented To prevent one death: 200 people need to be treated ( 100/ARR%) Time-5 years. Therefore 200 people over 5 years to prevent 1 case

A Control 6.5% B Treatm ent 4.6% Non fatal Myocardial Infarction Absolute Risk Reduction = A-B= 2.9% Number needed to treat 100 people, 2.9 heart attacks prevented To prevent one heart attack= 100/ARR%= 100/2.9 Over 5 years

Check list When you hear about a new drug or treatment, check both absolute and relative risk reduction figures Ask ( or calculate) number needed to treat Ask about possible harms Ask about costs

P values and Confidence Intervals ( CI) P value or probability value= “The probability of obtaining result at least as extreme if the null hypothesis was true” P <.05 means a less than 95 percent of the time you will get a similar result P<.01 means a less than 99% percent of the time you would get a similar result P values of.05 and less are acceptable

According to scientific convention, P<.05 is significant, and P<.01 is highly significant.

Confidence intervals (CI) The confidence level tells you the range within which a true value will lie. It is generally measured at the 95% level. For example, 31 ( 17-43) 95% CI would indicate that 95% probability that the real value is between 17 and 43.

5ekg&feature=related

From last week When evaluating research findings - Published or not published? - Quality of study: numbers of people or cases studied, methodology of study - Newsworthiness

Your course work Three news stories from journal articles Due Feb 28, March 28 and March 17(you can turn them in earlier if you wish) Length: words Go to Eureka alert, as well as Jama and BMJ Links to press releases on our course website Find an article that you think might be newsworthy and interesting.

Do some background research on the topic. Go to Pubmed for earlier studies Contact authors of paper, as well as people in Hong Kong who might have comments. Give yourself one week for each

Contacting paper authors Why? Not to “get a quote” To help bring out the significance, or importance of study To help you understand things you do not understand Read the paper and do research before getting in touch, so you do not ask basic questions

What I will look for Is the story newsworthy? Have you explained the research well? Have you looked at the costs and benefits (Look at the health news review website for an idea of what I will be looking for)